Harvard Bioscience Posts $0.58 Per-Share Q3 Loss
HBIO has more than doubled off its 52-week low of $4 on elevated volume (2.3× avg).
Summary
Harvard Bioscience reported a third-quarter loss of $2.62M, or $0.58 per share, on revenue of $22.2M, up 8% year over year and ahead of estimates. The company is coming off Q2 2026 revenue of $22.7M, up 11% year over year, when it raised full-year revenue guidance — so a $0.58 quarterly loss is a sharp swing against that improving top-line trend. With a market cap near $41M and the stock trading near its 52-week high of $9.32, the loss lands on a name that has already run hard. High debt costs and cash burn flagged in the last 10-Q remain the pressure points.
At the time of this announcement, HBIO was trading at $9.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.4M. The 52-week trading range was $4.00 to $9.32. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.